Literature DB >> 17150354

The metastatic cascade in prostate cancer.

Manit Arya1, Simon R Bott, Iqbal S Shergill, Hashim U Ahmed, Magali Williamson, Hiten R Patel.   

Abstract

Morbidity and mortality due to prostate cancer are mainly a result of prostate cancer metastases. After the initial neoplastic transformation of cells, the process of metastasis involves a series of sequential steps, which involve neoangiogenesis and lymphangiogenesis, loss of adhesion with migration away from the primary tumour and entry into the systemic vasculature or lymphatics. Metastatic growth in sites such as lymph nodes and bone marrow then involves the specific non-random homing of prostate cancer cells. An appreciation and understanding of this metastatic cascade in relation to prostate cancer is clinically important in order to stratify men with prostate cancer into prognostic groups. Moreover, it is crucial in the future development of therapies that can prevent metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150354     DOI: 10.1016/j.suronc.2006.10.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  40 in total

Review 1.  Isolated, disseminated and circulating tumour cells in prostate cancer.

Authors:  David Schilling; Tilman Todenhöfer; Jörg Hennenlotter; Christian Schwentner; Tanja Fehm; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

2.  Celiac and perigastric lymph node metastasis of prostate cancer diagnosed with endoscopic ultrasound-guided fine-needle aspiration.

Authors:  T Attila; R Ricketts-Loriaux; D A Sauer; D O Faigel
Journal:  Can J Gastroenterol       Date:  2009-07       Impact factor: 3.522

3.  Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion.

Authors:  Yirong Li; Martin Ligr; James P McCarron; Garrett Daniels; David Zhang; Xin Zhao; Fei Ye; Jinhua Wang; Xiaomei Liu; Iman Osman; Simon K Mencher; Hebert Lepor; Long G Wang; Anna Ferrari; Peng Lee
Journal:  Clin Cancer Res       Date:  2011-05-23       Impact factor: 12.531

4.  Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion.

Authors:  Esha T Shah; Akanksha Upadhyaya; Lisa K Philp; Tiffany Tang; Dubravka Skalamera; Jennifer Gunter; Colleen C Nelson; Elizabeth D Williams; Brett G Hollier
Journal:  Clin Exp Metastasis       Date:  2016-03-01       Impact factor: 5.150

Review 5.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

6.  Effects of Hedera helix L. extracts on rat prostate cancer cell proliferation and motility.

Authors:  Hatice Gumushan-Aktas; Seyhan Altun
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

7.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

8.  Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Authors:  Lei Gu; Pooja Talati; Paraskevi Vogiatzi; Ana L Romero-Weaver; Junaid Abdulghani; Zhiyong Liao; Benjamin Leiby; David T Hoang; Tuomas Mirtti; Kalle Alanen; Michael Zinda; Dennis Huszar; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-02-27       Impact factor: 6.261

Review 9.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

10.  Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.

Authors:  S Dasgupta; L M Wasson; N Rauniyar; L Prokai; J Borejdo; J K Vishwanatha
Journal:  Oncogene       Date:  2009-06-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.